When your time here on Earth is done, what will your legacy be? We all leave one behind, intentionally or unintentionally. What do you want to be remembered for? When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, I’d already retired once from a successful…
We all leave a legacy, so be sure to shape yours with intention
Treatment with GRI Bio‘s investigational oral therapy GRI-0621 appears to reduce markers of fibrosis, or scarring, in people with idiopathic pulmonary fibrosis (IPF), according to an interim analysis of biomarker data from an ongoing Phase 2a clinical trial. “These 6-week interim biomarker data, while early and based on…
During my journey with idiopathic pulmonary fibrosis, I’ve noticed periods of silence that affect not only patients, but also caregivers. I experienced my first significant such period about eight months after my diagnosis in January 2017. I took disability leave from my job as I was no longer able…
Researchers in China used machine learning — a type of artificial intelligence in which computers detect patterns in datasets and then make predictions — to create diagnostic and prognostic models for use in idiopathic pulmonary fibrosis (IPF). Using the new models, the team observed gene activity changes suggestive of…
When I talk to patients, caregivers, or family members, almost all of them can recall the details of the pertinent diagnosis. After all, it’s a monumental life event. What each of us hears and how it’s interpreted can vary. When I was diagnosed with idiopathic pulmonary fibrosis (IPF)…
CS014, a treatment candidate for idiopathic pulmonary fibrosis (IPF), was found to be safe and well tolerated in healthy volunteers in a Phase 1 clinical trial, according to new data from developer Cereno Scientific. Further, the experimental medication reached levels in the bloodstream that the company predicts will…
Some truly horrific events have occurred in recent weeks. The flash flooding that began in the early hours of July 4 along the Guadalupe River in Texas has claimed 134 lives as of this writing, with dozens more still missing or unaccounted for. Emergency situations are dangerous, but even more…
Endeavor Biomedicines’ oral treatment candidate taladegib (ENV-101) has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary fibrosis (IPF) In both regions, orphan drug status is intended to incentivize the development of medications for rare diseases. In the EU,…
Joy is a simple three-letter word, but it can be elusive at times for those of us in the pulmonary fibrosis community. Patients and caregivers alike may often feel like no joy is to be found. When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January…
An experimental oral therapy for idiopathic pulmonary fibrosis (IPF) has been tolerated well in an ongoing Phase 2 clinical trial, according to interim data announced by its developer GRI Bio. After reviewing interim data from 24 patients treated with GRI-0621 for six weeks, an independent data monitoring…
